Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 17/20 | 0.55 |
| ▸ | BCL2 | P10415 | 2/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | NEK4 | P51957 | 2/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.48 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.48 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.48 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.48 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.48 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.48 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.48 |
| ▸ | EEF2K | O00418 | 1/20 | 0.48 |
| ▸ | MARK3 | P27448 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | BCL6 | P41182 | 1/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.48 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30000817 | 1.00 | MCL1 (0.55) | MCL1BCL2ALBBCL2L1NEK4 | |
| SCHEMBL22436687 | 0.93 | MCL1 (0.47) | MCL1BCL2ALBBCL2L1NEK4 | |
| SCHEMBL29999937 | 0.93 | MCL1 (0.47) | MCL1BCL2ALBBCL2L1NEK4 | |
| SCHEMBL19615272 | 0.91 | MCL1 (0.60) | MCL1BCL2ALBBCL2L1NEK4 | |
| SCHEMBL30000950 | 0.89 | MCL1 (0.55) | MCL1BCL2ALBBCL2L1NEK4 | |
| SCHEMBL22436876 | 0.89 | MCL1 (0.55) | MCL1BCL2ALBBCL2L1NEK4 | |
| SCHEMBL4165286 | 0.88 | MCL1 (0.60) | MCL1BCL2ALBBCL2L1NEK4 | |
| SCHEMBL4158396 | 0.86 | MCL1 (0.51) | MCL1BCL2ALBBCL2L1NEK4 | |
| SCHEMBL4168695 | 0.85 | MCL1 (0.59) | MCL1BCL2ALBBCL2L1NEK4 | |
| SCHEMBL22436674 | 0.84 | MCL1 (0.46) | MCL1BCL2ALBBCL2L1NEK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152041-B2 | Macrocyclic fluorine substituted indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| CN-117957218-A | Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins | 凯普托尔治疗学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-111757884-B | Substituted macrocyclic indole derivatives | 拜耳股份公司 | 2023-12-19 | — | — | CN | disclosed |
| WO-2022255888-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| US-11440923-B2 | Substituted macrocyclic indole derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-09-13 | — | — | US | disclosed |
| US-20220281891-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-09-08 | — | — | US | disclosed |
| EP-3710449-B1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS, FOR USE IN THE TREATMENT OF CANCER | BROAD INST INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3710449-B1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS, FOR USE IN THE TREATMENT OF CANCER | BROAD INST INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11286263-B2 | Macrocyclic fluorine substituted indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11286263-B2 | Macrocyclic fluorine substituted indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210079018-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-18 | — | — | US | disclosed |
| US-20210079018-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-18 | — | — | US | disclosed |
| CN-111757884-A | Substituted macrocyclic indole derivatives | 拜耳股份公司 | 2020-10-09 | — | — | CN | disclosed |
| EP-3710451-A1 | SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2020-09-23 | — | — | EP | disclosed |
| EP-3710449-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS, FOR USE IN THE TREATMENT OF CANCER | The Broad Institute, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152041-B2 | Macrocyclic fluorine substituted indole derivatives | FOXM1, CCNT2, CCND2 | MCL1 34/4885BCL2 550/4885ALB 3104/4885 |
| US-11286263-B2 | Macrocyclic fluorine substituted indole derivatives | FOXM1, CCNT2, CCND2 | MCL1 34/4885BCL2 550/4885ALB 3104/4885 |
| US-20210079018-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES | FOXM1, CCNT2, CCND2 | MCL1 34/4885BCL2 550/4885ALB 3104/4885 |
| US-11440923-B2 | Substituted macrocyclic indole derivatives | FOXM1, CCND2, CCNI | MCL1 53/4885BCL2 635/4885ALB 2689/4885 |
| US-20220281891-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES | FOXM1, CCNT2, CCND2 | MCL1 34/4885BCL2 550/4885ALB 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.